IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE
- 27 July 2006
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 178 (1-2) , 1-8
- https://doi.org/10.1016/j.jneuroim.2006.05.030
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Peptide-based therapeutic vaccines for allergic and autoimmune diseasesNature Medicine, 2005
- Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemiaBlood, 2003
- Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [RETIRED]Neurology, 2002
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- Regulatory Th2-type T cell Lines Against Insulin and GAD Peptides Derived from Orally- and Nasally-Treated NOD Mice Suppress DiabetesJournal of Autoimmunity, 1999
- Role of interleukin 10 in specific immunotherapy.Journal of Clinical Investigation, 1998
- Inflammation in EAE: Role of chemokine/cytokine expression by resident and infiltrating cellsNeurochemical Research, 1996
- Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes.The Journal of Experimental Medicine, 1996
- Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinityInternational Immunology, 1993
- Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi miceJournal of Neuroimmunology, 1990